
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Gilead Sciences Inc (GILD) is a leading drug manufacturers-general business with stocks listed in the US. It opened the day at US$62.77 after a previous close of US$63.08. During the day the price has varied from a low of USD62.63 to a high of USD63.53. The latest price was USD62.83 (25 minute delay). Gilead Sciences is listed on the NASDAQ. All prices are listed in US Dollars.
How to buy shares in Gilead Sciences
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Gilead Sciences. Find the share by name or ticker symbol: GILD. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Gilead Sciences reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$63.08, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Gilead Sciences, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Gilead Sciences. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Our top pick for
US stocks

Our top pick for
Long-term investing

Our top pick for
Low-cost broker

What's in this guide?
- Gilead Sciences key stats
- Compare share trading platforms
- Is Gilead Sciences stock a buy or sell?
- Gilead Sciences performance over time
- Is Gilead Sciences suitable for ethical investing?
- Are Gilead Sciences shares over-valued?
- Gilead Sciences's financials
- How volatile are Gilead Sciences shares?
- Does Gilead Sciences pay a dividend?
- Have Gilead Sciences shares ever split?
- Other common questions
Gilead Sciences stock price (NASDAQ:GILD)
Use our graph to track the performance of GILD stocks over time.Gilead Sciences shares at a glance
Open | US$62.77 |
---|---|
High | US$63.53 |
Low | US$62.63 |
Close | US$62.83 |
Previous close | US$63.08 |
Change | US$-0.25 |
Change % | -0.3963% |
Volume | 6,308,622 |
52-week range | US$55.9001 - US$72.2839 |
---|---|
50-day moving average | US$62.0314 |
200-day moving average | US$65.4829 |
Target price | US$69.21 |
PE ratio | 17.6201 |
Dividend yield | US$2.86 (4.63%) |
Earnings per share (TTM) | US$3.58 |
Compare trading apps to buy Gilead Sciences shares
Is it a good time to buy Gilead Sciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Gilead Sciences price performance over time
Historical closes compared with the last close of $62.83
1 week (2022-06-21) | 3.83% |
---|---|
1 month (2022-05-26) | -2.54% |
6 months (2021-12-27) | -13.78% |
1 year (2021-06-28) | -7.19% |
---|---|
2 years (2020-06-26) | -15.74% |
3 years (2019-06-28) | -7.00% |
5 years (2017-06-28) | -12.64% |
Stocks similar to Gilead Sciences
Is Gilead Sciences under- or over-valued?
Valuing Gilead Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Gilead Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Gilead Sciences's P/E ratio
Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Gilead Sciences shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Gilead Sciences's PEG ratio
Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.517. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Gilead Sciences's EBITDA
Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$13.2 billion (£10.8 billion).
The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure a its profitability.
Gilead Sciences financials
Revenue TTM | US$27.5 billion |
---|---|
Operating margin TTM | 40.5% |
Gross profit TTM | US$21.8 billion |
Return on assets TTM | 10.65% |
Return on equity TTM | 23.1% |
Profit margin | 16.43% |
Book value | 15.878 |
Market capitalisation | US$79.8 billion |
TTM: trailing 12 months
Gilead Sciences's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Gilead Sciences.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Gilead Sciences's total ESG risk score
Total ESG risk: 22.15
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Gilead Sciences's overall score of 22.15 (as at 01/01/2019) is pretty good – landing it in it in the 31st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Gilead Sciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Gilead Sciences's environmental score
Environmental score: 0.53/100
Gilead Sciences's environmental score of 0.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Gilead Sciences's social score
Social score: 12.97/100
Gilead Sciences's social score of 12.97 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Gilead Sciences's governance score
Governance score: 7.65/100
Gilead Sciences's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Gilead Sciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Gilead Sciences's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Gilead Sciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Gilead Sciences has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Gilead Sciences Inc was last rated for ESG on: 2019-01-01.
Total ESG score | 22.15 |
---|---|
Total ESG percentile | 30.98 |
Environmental score | 0.53 |
Environmental score percentile | 2 |
Social score | 12.97 |
Social score percentile | 2 |
Governance score | 7.65 |
Governance score percentile | 2 |
Level of controversy | 2 |
Gilead Sciences share dividends
Dividend payout ratio: 39.29% of net profits
Recently Gilead Sciences has paid out, on average, around 39.29% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.63% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Gilead Sciences shareholders could enjoy a 4.63% return on their shares, in the form of dividend payments. In Gilead Sciences's case, that would currently equate to about $2.86 per share.
While Gilead Sciences's payout ratio might seem fairly standard, it's worth remembering that Gilead Sciences may be investing much of the rest of its net profits in future growth.
Gilead Sciences's most recent dividend payout was on 29 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 14 June 2022 (the "ex-dividend date").
Have Gilead Sciences's shares ever split?
Gilead Sciences's shares were split on a 2:1 basis on 28 January 2013. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Gilead Sciences shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Gilead Sciences shares which in turn could have impacted Gilead Sciences's share price.
Gilead Sciences share price volatility
Over the last 12 months, Gilead Sciences's shares have ranged in value from as little as US$55.9001 up to US$72.2839. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.3798. This would suggest that Gilead Sciences's shares are less volatile than average (for this exchange).
Gilead Sciences overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Gilead Sciences in the news
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
Gilead (GILD) HIV Candidate Gets Positive CHMP Recommendation
Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases
Frequently asked questions
More guides on Finder
-
How to buy Kincora Copper (KCC) shares
Steps to owning and managing Kincora Copper shares.
-
How to invest in the Dragon Mountain Gold IPO
Everything we know about the Dragon Mountain Gold IPO, plus information on how to buy in.
-
How to buy Arcadia Minerals (AM7) shares
Steps to owning and managing Arcadia Minerals shares.
-
How to buy Nexgen Energy (NXG) shares
Steps to owning and managing Nexgen Energy shares.
-
How to buy Keypath Education (KED) shares
Steps to owning and managing Keypath Education shares.
-
What are green bonds and how do they impact the world?
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
-
5 best ways to invest money in Australia in 2022
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
-
How to buy EBR Systems (EBR) shares
Steps to owning and managing EBR Systems shares.
-
How to buy 5E Advanced Materials (5EA) shares
Steps to owning and managing 5E Advanced Materials shares.
-
How to buy Leo lithium shares
Steps to owning and managing Leo lithium shares.
Ask an Expert